NYSE:GMED - Globus Medical Stock Price, Forecast & News

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Globus Medical Inc (NYSE:GMED) released its earnings results on Wednesday, November, 6th. The medical device company reported $0.43 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.42 by $0.01. The medical device company had revenue of $196.22 million for the quarter, compared to analyst estimates of $185.86 million. Globus Medical had a net margin of 19.03% and a return on equity of 13.09%. The business's quarterly revenue was up 15.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.39 earnings per share. View Globus Medical's Earnings History.

Globus Medical is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Globus Medical.

Globus Medical updated its FY20 earnings guidance on Wednesday, January, 8th. The company provided earnings per share guidance of $1.82 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.92. The company issued revenue guidance of $850.00 million, compared to the consensus revenue estimate of $854.27 million.

9 brokerages have issued 1 year target prices for Globus Medical's shares. Their forecasts range from $60.00 to $67.00. On average, they anticipate Globus Medical's share price to reach $64.43 in the next twelve months. This suggests a possible upside of 21.8% from the stock's current price. View Analyst Price Targets for Globus Medical.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Globus Medical.

Media headlines about GMED stock have been trending somewhat positive this week, according to InfoTrie. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Globus Medical earned a news impact score of 1.8 on InfoTrie's scale. They also assigned press coverage about the medical device company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Globus Medical.

Globus Medical saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 1,340,000 shares, an increase of 14.5% from the November 28th total of 1,170,000 shares. Based on an average trading volume of 467,500 shares, the short-interest ratio is currently 2.9 days. Currently, 1.8% of the shares of the stock are short sold. View Globus Medical's Current Options Chain.

Some companies that are related to Globus Medical include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include AbbVie (ABBV), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY), Alibaba Group (BABA), Novartis (NVS), Intuitive Surgical (ISRG), Bausch Health Companies (BHC), Johnson & Johnson (JNJ), Pfizer (PFE) and Intel (INTC).

Globus Medical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Marathon Asset Management LLP (0.68%), Boston Trust Walden Corp (0.43%), Zeke Capital Advisors LLC (0.14%), Louisiana State Employees Retirement System (0.02%), State of Alaska Department of Revenue (0.01%) and Compass Ion Advisors LLC (0.01%). Company insiders that own Globus Medical stock include Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz, James R Tobin, Kelly Huller and Steven Payne. View Institutional Ownership Trends for Globus Medical.

GMED stock was sold by a variety of institutional investors in the last quarter, including Marathon Asset Management LLP, Zeke Capital Advisors LLC and State of Alaska Department of Revenue. Company insiders that have sold Globus Medical company stock in the last year include Anthony L Williams, David D Davidar, James R Tobin and Kelly Huller. View Insider Buying and Selling for Globus Medical.

GMED stock was acquired by a variety of institutional investors in the last quarter, including Compass Ion Advisors LLC, Boston Trust Walden Corp, Cerebellum GP LLC, HWG Holdings LP, Exchange Traded Concepts LLC, Savior LLC, Nisa Investment Advisors LLC and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Globus Medical.

Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GMED stock can currently be purchased for approximately $52.88.

Globus Medical has a market capitalization of $5.26 billion and generates $712.97 million in revenue each year. The medical device company earns $156.47 million in net income (profit) each year or $1.67 on an earnings per share basis. Globus Medical employs 1,800 workers across the globe.View Additional Information About Globus Medical.

The official website for Globus Medical is http://www.globusmedical.com/.

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]